CompletedNCT02192554
Safety Follow-up Study for Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Previously Participated in a Double-blind Trial of Brexpiprazole or Placebo
Observational studyMultiple countriesMental health
Understand this study
- Listed locations
- Tuscaloosa and 83 more locationsSee all locations and recruitment
Study information
Study start dateStarted: June 2014
- Recruitment status
- Completed
- Enrollment listed in the registry
- 450
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Sponsor type
- Pharmaceutical company
- Study type
- Observational
- Intervention type
- Interview / survey / observational
- Study phase
- Not clearly listed
- Locations
- United States, France, Canada, ...
- Age range
- Not clearly listed
- Official registry ID
- NCT02192554
- Official title
Show the full official title
A 2-Month, Observational, Rollover Trial to Evaluate the Safety of Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Were Previously Treated With Brexpiprazole (OPC 34712) or Placebo in a Phase 3, Double-blind Trial
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Tuscaloosa, United States · Costa Mesa, United States · Lakewood, United States
66 more locations
- Orange, United States
- Redlands, United States
- Bradenton, United States
- Hialeah, United States
- Miami, United States
- Miami Springs, United States
- North Miami, United States
- Orange City, United States
- Sarasota, United States
- Atlanta, United States
- Suwanee, United States
- Quincy, United States
- St Louis, United States
- Toms River, United States
- Brooklyn, United States
- New Hyde Park, United States
- Charlotte, United States
- Hickory, United States
- Raleigh, United States
- Dallas, United States
- Waukesha, United States
- Burgas, Bulgaria
- Kardzhali, Bulgaria
- Rousse, Bulgaria
- Sofia, Bulgaria
- Varna, Bulgaria
- Veliko Tarnovo, Bulgaria
- Penticton, Canada
- Kentville, Canada
- Zagreb, Croatia
- Bourg N Bresse, France
- Douai, France
- Élancourt, France
- Toulouse, France
- Mittweida, Germany
- Berlin, Germany
- Bochum, Germany
- Cologne, Germany
- Westerstede, Germany
- Saint Petersburg, Russia
- Samara, Russia
- Saratov, Russia
- Tonnelniy, Russia
- Yekaterinburg, Russia
- Belgrade, Serbia
- Kovin, Serbia
- Kragujevac, Serbia
- Niš, Serbia
- Novi Kneževac, Serbia
- Novi Sad, Serbia
- Ljubljana, Slovenia
- Maribor, Slovenia
- Sempeter pri Gorici, Slovenia
- Pamplona, Spain
- Salamanca, Spain
- Valencia, Spain
- Zamora, Spain
- Kharkiv, Ukraine
- Kherson, Ukraine
- Kiev, Ukraine
- Lviv, Ukraine
- Odesa, Ukraine
- Poltava, Ukraine
- Vinnytsia, Ukraine
- Torpoint, United Kingdom
- Russia
Questions about this study
Who is behind this study?
The study sponsor is Otsuka Pharmaceutical Development & Commercialization, Inc., a pharmaceutical company.
